European clinical guidelines for Tourette syndrome and other tic disorders. Part II: Pharmacological treatment

Veit Roessner, Kerstin J. Plessen, Aribert Rothenberger, Andrea G. Ludolph, Renata Rizzo, Liselotte Skov, Gerd Strand, Jeremy S. Stern, Cristiano Termine, Pieter J. Hoekstra, Christos Androutsos, Harald Aschauer, Gillian Baird, Netty Bos-Veneman, Ariana Brambilla, Francesco Cardona, Danielle C. Cath, Andrea E. Cavanna, Virginie Czernecki, Sandra DehningAlan Eapter, Luca Farkas, Julia Gadaros, Andreas Hartmann, Elizabeth Hauser, Isabel Heyman, Tammy Hedderly, Anne Korsgaard, Georgina M. Jackson, Linnea Larsson, Davide Martino, Claudia Menghetti, Nanette Mol Debes, Norbert Muller, Kirsten Muller-Vahl, Alexander Munchau, Tara Murphy, Richard Musil, Peter Nagy, Judith Nurnberger, Ben Oostra, Perry Paschou, Massimo Pasquini, Mauro Porta, Hugh Rickards, Mary M. Robertson, Domenico Servello, Zsannett Tarnok, Jolande Van Der Griendt, Cara Verdellen, Veerle Visser-Vandewalle, Ebba Wannag, Tomas Wolanczyck

Research output: Contribution to journalArticle

Abstract

To develop a European guideline on pharmacologic treatment of Tourette syndrome (TS) the available literature was thoroughly screened and extensively discussed by a working group of the European Society for the Study of Tourette syndrome (ESSTS). Although there are many more studies on pharmacotherapy of TS than on behavioral treatment options, only a limited number of studies meets rigorous quality criteria. Therefore, we have devised a two-stage approach. First, we present the highest level of evidence by reporting the findings of existing Cochrane reviews in this field. Subsequently, we provide the first comprehensive overview of all reports on pharmacological treatment options for TS through a MEDLINE, PubMed, and EMBASE search for all studies that document the effect of pharmacological treatment of TS and other tic disorders between 1970 and November 2010. We present a summary of the current consensus on pharmacological treatment options for TS in Europe to guide the clinician in daily practice. This summary is, however, rather a status quo of a clinically helpful but merely low evidence guideline, mainly driven by expert experience and opinion, since rigorous experimental studies are scarce.

Original languageEnglish
Pages (from-to)173-196
Number of pages24
JournalEuropean Child and Adolescent Psychiatry
Volume20
Issue number4
DOIs
Publication statusPublished - Apr 2011

Keywords

  • Guidelines
  • Pharmacologic
  • Tics
  • Tourette
  • Treatment

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pediatrics, Perinatology, and Child Health

Fingerprint Dive into the research topics of 'European clinical guidelines for Tourette syndrome and other tic disorders. Part II: Pharmacological treatment'. Together they form a unique fingerprint.

  • Cite this

    Roessner, V., Plessen, K. J., Rothenberger, A., Ludolph, A. G., Rizzo, R., Skov, L., Strand, G., Stern, J. S., Termine, C., Hoekstra, P. J., Androutsos, C., Aschauer, H., Baird, G., Bos-Veneman, N., Brambilla, A., Cardona, F., Cath, D. C., Cavanna, A. E., Czernecki, V., ... Wolanczyck, T. (2011). European clinical guidelines for Tourette syndrome and other tic disorders. Part II: Pharmacological treatment. European Child and Adolescent Psychiatry, 20(4), 173-196. https://doi.org/10.1007/s00787-011-0163-7